BMS-986165
CAS No. 1609392-27-9
BMS-986165( —— )
Catalog No. M21721 CAS No. 1609392-27-9
BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 153 | In Stock |
|
| 5MG | 140 | In Stock |
|
| 10MG | 261 | In Stock |
|
| 25MG | 410 | In Stock |
|
| 50MG | 593 | In Stock |
|
| 100MG | 844 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-986165
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.
-
DescriptionBMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.BMS-986165 maintains excellent potency in human and mouse whole blood (IC50s=13 and 100 nM, respectively) and shows no significant hERG inhibition in the flux assay (IC50>80 μM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1609392-27-9
-
Formula Weight425.46
-
Molecular FormulaC??H??D?N?O?
-
Purity>98% (HPLC)
-
SolubilityDMSO : 37.5 mg/mL (88.14 mM; Need ultrasonic)
-
SMILESO=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18.
2. Catlett I, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Annals of the Rheumatic Diseases 2017;76:859.
molnova catalog
related products
-
ZM39923 hydrochlorid...
ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1.
-
TG-101209
A potent, selective, orally bioavailable JAK2 inhibitor with IC50 of 6 nM; also inhibits FLT3 (IC50=25 nM) and RET (IC50=17 nM) kinases, weakly inhibits JAK3 (IC50=168 nM).
-
PF-04965842
PF-04965842 (Abrocitinib, PF04965842) is a potent, selective, orally bioavailable JAK1 inhibitor with IC50 of 29 nM.
Cart
sales@molnova.com